Calliditas Therapeutics AB Operating Income

Calliditas Therapeutics AB (CALT) currently reports a operating income of $-370M as of June 2024. That compares with $-220M in the prior-year period — down 68.8% year over year. Use the charts on this page to explore Calliditas Therapeutics AB's operating income history and peer comparisons.

Calliditas Therapeutics AB's operating income decreased from $-220M to $-370M — a 68.8% year-over-year decrease (period ending June 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Calliditas Therapeutics AB reported $-370M in operating income as of June 2024. That compares with $-220M in the prior-year period — down 68.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-370M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Calliditas Therapeutics AB, and consider following CALT for alerts when major investors trade the stock.

Calliditas Therapeutics AB is classified in the Healthcare sector. On operating income, it currently shows $-370M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CALT with unrelated industries.